Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of NTHi-Mcat Vaccine Following Shingrix in Healthy Smokers
NCT03894969Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2019
- Primary completion
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of GSK3277511A in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by GSK. Primary endpoint: Anti-Protein D, Anti-Protein E, Anti-PilA and Anti-UspA2 Adjusted Geometric Mean Concentrations. Started Apr 2019; status: completed.
02
Drugs
GSK3277511A
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03894969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894969.